دورية أكاديمية
أعرض في EDS

Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats

التفاصيل البيبلوغرافية
العنوان: Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
المؤلفون: Shahinaze A. Fouad, Mahmoud H. Teaima, Mostafa I. Gebril, Fathy I. Abd Allah, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal
المصدر: Drug Delivery, Vol 30, Iss 1 (2023)
بيانات النشر: Taylor & Francis Group, 2023.
سنة النشر: 2023
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: Diabetes mellitus (type II), repaglinide, niosomes, coprocessed excipients, dysphagia, chewable tablets, Therapeutics. Pharmacology, RM1-950
الوصف: AbstractRepaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG into niosomal formulations using cholesterol,span 60 and peceolTM. The optimized niosomal formulation (ONF) showed particle size 306.60 ± 84.00 nm, zeta potential −38.60 ± 1.20 mV, polydispersity index 0.48 ± 0.05 and entrapment efficiency 92.00 ± 2.60%. ONF showed > 65% RPG release that lasted for 3.5 h, and significantly higher sustained release compared to Novonorm® tablets after 6 h (p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 10717544
1521-0464
1071-7544
Relation: https://doaj.org/toc/1071-7544; https://doaj.org/toc/1521-0464
DOI: 10.1080/10717544.2023.2181747
URL الوصول: https://doaj.org/article/3ba05543f1014e0283e9f324dd9f7d65
رقم الأكسشن: edsdoj.3ba05543f1014e0283e9f324dd9f7d65
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:10717544
15210464
DOI:10.1080/10717544.2023.2181747